Display options
Cite
Khan SH, Hassan MU, Bhau RS. Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India. Indian J Nucl Med. 2015;30(3):227-32doi: 10.4103/0972-3919.158530.
Khan, S. H., Hassan, M. U., & Bhau, R. S. (2015). Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India. Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India, 30(3), 227-32. https://doi.org/10.4103/0972-3919.158530
Khan, Shoukat Hussain, et al. "Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India." Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India vol. 30,3 (2015): 227-32. doi: https://doi.org/10.4103/0972-3919.158530
Khan SH, Hassan MU, Bhau RS. Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India. Indian J Nucl Med. 2015 Jul-Sep;30(3):227-32. doi: 10.4103/0972-3919.158530. PMID: 26170565; PMCID: PMC4479911.
Copy Download .nbib Format: NLM
Share it on

Indian J Nucl Med. 2015 Jul-Sep;30(3):227-32. doi: 10.4103/0972-3919.158530.

Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India.

Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India

Shoukat Hussain Khan, Masood Ul Hassan, Rajesh Singh Bhau

Affiliations

  1. Department of Nuclear Medicine, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.
  2. Department of Radiotherapy, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.

PMID: 26170565 PMCID: PMC4479911 DOI: 10.4103/0972-3919.158530

Abstract

OBJECTIVE: The aim of the study was to study the clinical profile in patients of differentiated thyroid cancer (DTC) with Iodine-131 avid distant metastasis at presentation. The study also attempted to evaluate factors influencing survival among these patients.

MATERIAL AND METHODS: The cohort includes 35 patients (26 Female, 9 Male) studied retrospectively and prospectively over a period of 5 years at the Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India.

RESULTS: The five years cause specific survival among patients of DTC with distant metastasis in the study group was 74.3%. The mean age at presentation was 41.4 years with female patients outnumbering the male patients in a ratio of 5:1. Papillary histopathology was the commonest in 65.7% followed by Follicular in 31.4% and poorly differentiated cancer in 2.9% of patients.31.4% 0f patients presented with relatively advanced AJC/UICC tumor stage of T3-T4. Bone was the commonest site of metastasis in 42.85% of patients followed by lung in 40% 0f patients. 82.9% of patients had only single organ metastasis. Therapeutic Radioiodine was administered in 31 (88.6%) patients. On univariate analysis of various factors that may be influencing the cause specific survival at 5 years, age ≥ 45 years, T3-T4 tumor stage, regional lymph node metastasis, follicular histopathology and non administration of radioiodine revealed significant (P<0.05) association with a poor 5 year survival. However multivariate analysis identified advanced tumor stage (T3-T4) and non administration of radioiodine to be the only independent factors associated with poor survival.

CONCLUSION: Patients of differentiated thyroid cancer with distant metastasis having advanced tumor stage (T3-T4) and those in whom therapeutic radioiodine (I-131) is not administered seem to have an unfavorable prognosis in terms of a 5 years cause specific survival.

Keywords: Cause-specific survival; differentiated thyroid cancer; distant metastasis; radioiodine

References

  1. Am J Surg. 1997 Nov;174(5):474-6 - PubMed
  2. J Clin Endocrinol Metab. 1986 Oct;63(4):960-7 - PubMed
  3. J Cancer Epidemiol. 2013;2013:965212 - PubMed
  4. Ann Surg Oncol. 2007 May;14(5):1551-9 - PubMed
  5. J Clin Endocrinol Metab. 1988 Sep;67(3):501-8 - PubMed
  6. Am J Med. 1994 Nov;97(5):418-28 - PubMed
  7. Clin Endocrinol (Oxf). 2005 Jul;63(1):87-93 - PubMed
  8. Thyroid. 2009 Nov;19(11):1167-214 - PubMed
  9. Ann Oncol. 2012 Oct;23 Suppl 7:vii110-9 - PubMed
  10. Clin Endocrinol (Oxf). 1997 Dec;47(6):713-20 - PubMed
  11. J Clin Endocrinol Metab. 2010 Jun;95(6):2588-95 - PubMed
  12. Curr Opin Oncol. 2014 Jan;26(1):1-7 - PubMed
  13. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  14. Clin Nucl Med. 2009 Nov;34(11):756-61 - PubMed

Publication Types